Picture loading failed.

Anti-APP therapeutic antibody (Pre-made Crenezumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-122-1mg 1mg 3090
GMP-Bios-ab-122-10mg 10mg 21890
GMP-Bios-ab-122-100mg 100mg 148000
GMP-Bios-ab-122-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-APP therapeutic antibody (Pre-made Crenezumab biosimilar,Whole mAb)
INN Name Crenezumab
TargetAPP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5vzx:HL:EI/5vzy:HL
99% SI Structure5kmv:HL:EI
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAC Immune;Genentech;Universidad de Antioquia
Conditions Approvedna
Conditions ActiveAlzheimer's disease
Conditions Discontinuedna
Development Techna